LabCorp 2014 Annual Report Download - page 15

Download and view the complete annual report

Please find page 15 of the 2014 LabCorp annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 128

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128

13
Testing Services
Core Testing
The Company offers a broad range of clinical laboratory tests and procedures. Several hundred of these are frequently used
in general patient care by physicians to establish or support a diagnosis, to monitor treatment or medication, or to search for an
otherwise undiagnosed condition. The most frequently-requested of these core tests include blood chemistry analyses, urinalyses,
blood cell counts, thyroid tests, Pap tests, Hemoglobin A1C, PSA, STD tests (Ct, Ng, Tv, HIV), HCV tests, microbiology cultures
and procedures, and alcohol and other substance-abuse tests. These core procedures are most often used by physicians in their
outpatient office practices. Physicians may elect to send such procedures to an independent laboratory (including hospital
laboratories) or they may choose to establish their own laboratory to perform some of the tests.
The Company performs this group of core tests in each of its primary laboratories. This testing constitutes a majority of the
tests performed by the Company. The Company generally performs and reports most core procedures within 24 hours, utilizing
a variety of sophisticated and computerized laboratory testing instruments.
Specialty Testing
The Company’s Specialty Testing Group performs esoteric testing, cancer diagnostics, clinical trials central lab services
and other complex procedures. The Company's specialty testing businesses and their areas of expertise are summarized in the
chart below.
The Specialty Testing Group offers advanced methods and access to scientific expertise in the following disciplines:
Anatomic Pathology/Oncology. The Company offers advanced comprehensive tumor tissue analysis, including
immunohistochemistry (IHC), cancer cytogenetics and fluorescence in situ hybridization (FISH) through its DIANON
Pathology (“DIANON”) and Integrated Oncology specialty testing laboratories. Applications for molecular diagnostics
continue to increase in oncology for both the analysis of leukemia as well as the assessment of solid tumors. In cancers such
as colon and lung cancer, assays such as K-ras, BRAF and EGFR mutation analysis are associated with appropriate therapy
choices for a given patient (Pharmacogenomics).
Cardiovascular Disease. The Company's cardiovascular menu includes core cholesterol tests and expanded lipid profiles
as well as a metabolic syndrome profile and tests for thrombosis and stroke. The Company also offers complete testing for
monitoring disease progression and response to therapy.
Coagulation. The Company offers an extensive menu of tests for hemostasis and thrombosis, including bleeding profiles